Who We Are
What We Do
Corporate Responsibility
Patients and HCPS
Contact us
Careers | Investors | Patients and HCPS | Contact us
Careers Investors Patients and HCPS Contact us
Home / Company News / Gan & Lee Pharmaceuticals' Insulin Glargine Injection Prefilled Pen Approved in Mexico
Gan & Lee Pharmaceuticals' Insulin Glargine Injection Prefilled Pen Approved in Mexico

Beijing, China, May 23, 2024 — Gan & Lee Pharmaceuticals (referred to as Gan & Lee, stock code: 603087. SH), a global biopharmaceutical company, has recently received registration approval for its insulin glargine injection prefilled pen from Mexico's Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). This approval marks Gan & Lee's first entry into the Mexican market as a Marketing Authorization Holder (MAH), officially granting the company commercial authorization to sell its insulin glargine injection prefilled pen in Mexico.

Mexico, located in the southern part of North America, has a population of 130 million as of 20231. In 2022, its per capita GDP was $11,496.5 (international exchange rate)2. According to the 10th edition of the International Diabetes Federation (IDF) Diabetes Atlas (2021), approximately 14.12 million people aged 20-79 in Mexico had diabetes in 2021, with an annual per capita diabetes-related expenditure of $1,412.3. The prevalence of diabetes among adults in this age group was 16.9%3. The approval of Gan & Lee’s insulin glargine product will introduce high-quality and affordable insulin to the Mexican market, providing more treatment options for local diabetes patients.


The launch of Gan & Lee’s insulin glargine injection prefilled pen in Mexico will help to reduce the financial burden of diabetes care. Gan & Lee will collaborate closely with local medical institutions to ensure the product's accessibility and affordability. Moreover, it will actively participate in the prevention and treatment of diabetes in Mexico, to improve public health.


Having secured drug registration and commercialization rights in 21 countries and regions Gan & Lee is continuously broadening its international market presence. With the bright vision of “health without borders,” Gan & Lee will continue to explore international markets, drive technological innovation, enhance production efficiency and product quality, and deliver effective treatment solutions to patients worldwide.



1. Overview of Mexico: Country Profile - Ministry of Foreign Affairs of the People's Republic of China (2024, January). https://www.mfa.gov.cn/web/gjhdq_676201/gj_676203/bmz_679954/1206_680604/1206x0_680606/

2. The World Bank. (2024). Mexico. The World Bank. Retrieved May 21, 2024, from https://data.worldbank.org/country/mexico

3. IDF Diabetes Atlas 10th edition 2021. Available at: https://diabetesatlas.org/atlas/tenth-edition/


About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.


Copyright © 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP备10213074号-1 | 京公网安备 11011202003900号
Our websites


I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.